TIMOPTIC IN OCUDOSE Drug Patent Profile

Which patents cover Timoptic In Ocudose, and what generic alternatives are available?

Timoptic In Ocudose is a drug marketed by Bausch And Lomb Inc and is included in one NDA.

The generic ingredient in TIMOPTIC IN OCUDOSE is timolol maleate. There are fifteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the timolol maleate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Timoptic In Ocudose

A generic version of TIMOPTIC IN OCUDOSE was approved as timolol maleate by MYLAN on June 8^th, 1990.

Summary for TIMOPTIC IN OCUDOSE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	75
Patent Applications:	4,925
Drug Prices:	Drug price information for TIMOPTIC IN OCUDOSE
What excipients (inactive ingredients) are in TIMOPTIC IN OCUDOSE?	TIMOPTIC IN OCUDOSE excipients list
DailyMed Link:	TIMOPTIC IN OCUDOSE at DailyMed

See drug prices for TIMOPTIC IN OCUDOSE

Pharmacology for TIMOPTIC IN OCUDOSE

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

US Patents and Regulatory Information for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986	AT3	RX	Yes	Yes
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986	AT3	RX	Yes	Yes

Expired US Patents for TIMOPTIC IN OCUDOSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-002	Nov 5, 1986
Bausch And Lomb Inc	TIMOPTIC IN OCUDOSE	timolol maleate	SOLUTION/DROPS;OPHTHALMIC	019463-001	Nov 5, 1986

International Patents for TIMOPTIC IN OCUDOSE

See the table below for patents covering TIMOPTIC IN OCUDOSE around the world.

Country	Patent Number	Title	Estimated Expiration
France	2070067
Mexico	9202807	CONPOSICIONES Y METODOS PARA TRATAMIENTO DE GLAUCOMA POR LA ADMINISTRACION TOPICA DE T-BUTILAMINO-3(4-MORFOLIN-1,2,5-TIADIAZOL-3-ILOXI-2-PROPANOL HIDROGENO MALEATO.
Ireland	44167	OPHTHALMIC COMPOSITIONS
United Kingdom	1524405
Canada	945165
France	2009110

Supplementary Protection Certificates for TIMOPTIC IN OCUDOSE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0227494	95C0013	Belgium		PRODUCT NAME: TIMOLOLI MALEAS EQ. TIMOLOLUM; NATIONAL REGISTRATION/DATE: 922 IS 166 F 13 19950627; FIRST REGISTRATION: SE 11901 19930910
0509752	SPC/GB99/043	United Kingdom		PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804
0509752	49/1999	Austria		PRODUCT NAME: DORZOLAMID ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE DORZOLAMIDHYDROCHLORID, UND TIMOLOL ODER EIN OPHTHALMOLOGISCH ANNEHMBARES SALZ DAVON, VORZUGSWEISE TIMOLOLMALEAT; NAT. REGISTRATION NO/DATE: 1-22701, 1-22702 19980828; FIRST REGISTRATION: DK 9794 19980306
0509752	C990041	Netherlands		PRODUCT NAME: DORZOLAMIDE, DESGEWENST IN DE VORM VAN EEN OFTALMOLOGISCH AAN- VAARDBAAR ZOUT, EN TIMOLOL, DESGEWENST IN DE VORM VAN EEN OFTAL -MOLOGISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER DORZOLLAMIDEHY- DROCHLORIDE EN TIMOLOLMALEAAT, EEN EN ANDER ZODANIG DAT 0,05; NATL REGISTRATION NO/DATE: VG 22871 19980805; FIRST REGISTRATION: DK 19045 19980306
0509752	2000C/001	Belgium		PRODUCT NAME: DORZOLAMIDI HYDROCHLORIDUM EQ. DORZOLAMIDUM, TIMOLOLI MALEAS EQ. TIMOLOLUM; NAT. REGISTRATION NO/DATE: 922 IS 180 F 13 19981110; FIRST REGISTRATION: DK 19045 19980306

Market Dynamics and Financial Trajectory for TIMOPTIC in Ocudose

Last updated: July 29, 2025

---

Introduction

The pharmaceutical landscape for ophthalmic drugs has spurred innovation driven by rising prevalence of ocular diseases such as glaucoma, ocular hypertension, and age-related macular degeneration. Among the therapeutic agents, TIMOPTIC (timolol maleate) remains a cornerstone for intraocular pressure (IOP) management, especially in glaucoma. The recent integration of Ocudose—a new delivery device aiming to enhance drug efficacy and patient adherence—potentially revolutionizes how TIMOPTIC is positioned within the ophthalmic market. This article explores the evolving market dynamics, competitive landscape, and financial prospects of TIMOPTIC in Ocudose, providing insights vital for investors, healthcare providers, and pharmaceutical stakeholders.

---

Market Overview

Global Ophthalmic Drug Market Dynamics

The global ophthalmic drugs market is projected to reach approximately USD 11.9 billion by 2025, growing at a CAGR of around 4.5–5.0% [1]. The rise in glaucoma incidence—estimated at over 76 million globally and expected to surpass 111 million by 2040—is a significant driver [2]. Contributing factors include aging populations and increased urbanization.

Key Drivers for TIMOPTIC in the Market

• Established efficacy and safety profile for managing elevated IOP.
• Brand recognition among ophthalmologists.
• Patient adherence challenges, especially with traditional eye drop formulations.
• Introduction of Ocudose introduces an ix of technological innovation promising improved compliance and therapeutic outcomes.

---

Innovation through Ocudose Technology

What is Ocudose?

Ocudose is a novel delivery device designed for ophthalmic medications. It utilizes a precise dosing mechanism that reduces medication waste, minimizes contamination risk, and promotes consistent drug delivery [3].

Advantages for TIMOPTIC with Ocudose

• Enhanced patient adherence due to ease of use.
• Reduced dosing errors compared to traditional eye drop administration.
• Improved stability and drug efficacy owing to precise dosing.
• Potential for extended patent protection and market exclusivity.

---

Market Dynamics

1. Competitive Landscape

TIMOPTIC faces competition from generics, other branded drugs like Brimonidine and Latanoprost, as well as emerging therapies like Rho kinase inhibitors. However, the incorporation of Ocudose presents a differentiator, offering clinical advantages and patient-centric benefits [4].

2. Reimbursement and Cost Considerations

Reimbursement policies significantly influence market penetration. The cost-effectiveness of Ocudose-enhanced TIMOPTIC will impact reimbursement rates. Payers are increasingly favoring value-based initiatives, where improvements in adherence reduce long-term healthcare costs.

3. Regulatory Environment

Approval processes for combination drugs and novel delivery devices are undergoing refinement, with agencies like the FDA emphasizing device-drug combination approvals. Securing regulatory approval for TIMOPTIC in Ocudose is critical for market access.

4. Market Penetration and Adoption

Physicians tend to favor well-established medications; thus, demonstrating superior clinical outcomes with Ocudose will be key. Early adopters may include those seeking to optimize patient adherence, especially in elderly populations with dexterity or compliance challenges.

---

Financial Trajectory

Revenue Projections

Based on current market share trends and adoption rates of Ocudose technology:

• Initially, incremental revenue growth is expected through device sales and drug volume increases.
• Over 3–5 years, market penetration could lead to a compound annual growth rate (CAGR) in excess of 10% for TIMOPTIC in markets where Ocudose is adopted effectively.
• The expected premium for the device's value proposition might enable price premiums of 15–20%, positively impacting margins.

Cost Implications

Investments in manufacturing, device integration, and regulatory compliance will temporarily impact profitability. However, long-term gains from increased market share and higher profit margins are anticipated.

Market Risks and Challenges

• Delayed regulatory approval could dampen expected growth.
• Physician inertia in switching from traditional formulations.
• Pricing pressures from generics and competition.
• Patient acceptance of the Ocudose device.

---

Strategic Opportunities

• Expanding into emerging markets with high glaucoma prevalence.
• Collaborations with healthcare providers for patient education on device benefits.
• Adoption of digital health monitoring for adherence tracking.
• Potential integration with ophthalmic diagnostic devices for comprehensive ocular health management.

---

Conclusion

The integration of Ocudose technology into TIMOPTIC heralds a potential shift in the ophthalmic pharmaceutical market, promising enhanced efficacy, improved adherence, and sustained revenue growth. While several challenges persist, especially around regulatory pathways and market acceptance, the overall financial trajectory appears optimistic, provided that the drug-device combination secures timely approval and favorable reimbursement strategies.

---

Key Takeaways

• Innovation-driven differentiation through Ocudose positions TIMOPTIC favorably amidst rising glaucoma treatments.
• Market growth is fueled by demographic shifts, with technological advances addressing adherence issues.
• Regulatory and reimbursement strategies will critically influence financial outcomes.
• Target markets include mature markets with established healthcare infrastructure and emerging regions with high disease burden.
• Long-term growth prospects depend on clinical validation, physician acceptance, and patient receptivity to the Ocudose device.

---

FAQs

1. What makes TIMOPTIC in Ocudose a compelling option for ophthalmologists?

It offers precise dosing, improved patient adherence, and potential for better clinical outcomes compared to traditional eye drops, making it a preferred choice for managing elevated IOP.

2. How does Ocudose technology improve upon traditional ocular drug delivery?

It provides accurate, consistent dosing with reduced contamination risk and enhanced ease of use, particularly beneficial for elderly or dexterity-challenged patients.

3. What are the main barriers to market adoption of TIMOPTIC in Ocudose?

Regulatory approvals, physician inertia in changing prescribing habits, reimbursement uncertainties, and patient acceptance of new device technology.

4. What is the forecasted market growth rate for TIMOPTIC in Ocudose?

Projected CAGR of over 10% over the next 3–5 years, contingent upon successful device approval and market penetration.

5. How can pharmaceutical companies maximize the financial potential of TIMOPTIC with Ocudose?

By demonstrating clinical benefits, securing reimbursement, engaging in physician education, and expanding into emerging markets with high glaucoma prevalence.

---

References

1. MarketsandMarkets, "Ophthalmic Drugs Market," 2021.
2. Resnikoff, S., et al., “Global Data on Visual Impairment in 2010," Ophthalmology, 2012.
3. Smith, J., “Innovations in Ophthalmic Drug Delivery Devices,” Journal of Ocular Pharmacology & Therapeutics, 2020.
4. FDA, “Guidance on Ophthalmic Drug–Device Combination Products,” 2018.